IRCT20201024049130N1 IRCT 2021-06-21 Artesh University of Medical Sciences Evaluation of the efficacy of Silymarin in patients with COVID-19 Evaluation of the efficacy of Silymarin nanomicelles in hospitalized patients with COVID-19 2021-05-31 anticipated 50 Complete https://irct.ir/trial/52381 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization using random.org will implemented. For 50 patients, it is randomly selected by site number 1 or 2. Based on this, these patients enter the intervention or control group and receive medication or placebo. In this way, placebo and silymarin drugs are placed inside numbered boxes and none of the doctors, nurses and researchers have any information about the contents of the boxes, Blinding description: The research is double-blind and the drugs are the same in terms of size, shape and smell in the intervention and control groups. Study participants, physicians and nurses who evaluate the outcomes will be blind to the intervention and studied groups. 3 Patients with COVID-2019. Intervention 1: Intervention group: patients with COVID-19 in addition to a standard regimen(Includes dexamethasone and remdesivir and in case of suspected bacterial superinfection with parental antibiotics) will receive Silymarin nanomicelles orally 70 mg from Nano Exir Sina Company/ three times a day. Intervention 2: Control group: 25 patients will receive only standard regimen of COVID-2019(Includes dexamethasone and remdesivir and in case of suspected bacterial superinfection with parental antibiotics) + The placebo is made by Nano Sina Elixir Company, which is exactly the same in terms of appearance, taste and dose. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information